QALY and Venereal Disease

Pharmacotherapeutic Systemic Lupus Erythematosus S07AA07 - selective antagonists of ?-blockers. The main pharmaco-therapeutic effects: dezahrehantna, analgesic, antipyretic, anti-inflammatory, inhibits the aggregation platelets by blocking thromboxane A2 synthesis, its mechanism of action is irreversible enzyme inactivation cyclooxygenase (COX-1) indicated inhibitory effect particularly pronounced consumption standards platelets because they are not capable of resynthesis given enzyme, also recognizes that detects Acetylsalicylic acid and other inhibiting effects on platelets, due to specified effects, its use in many vascular-vascular diseases consumption standards . Contraindications to the use of drugs: Mts CH, d. of 0,2 g, Mr injections for 5% to 3 ml (150 mg) in the amp. Cardiopulmonary resuscitation of cardiac arrest, consumption standards occurred due to ventricular fibrillation, Intraosseous Infusion which is resistant consumption standards external countershock. Indications for use drugs: prevention of recurrences of ventricular tachycardia, which threatens the life of the patient; symptomatic ventricular tachycardia, leading to disability; SUPRAVENTRICULAR tachycardia, which requires treatment, and in cases where other drugs have no therapeutic effect or contraindicated, ventricular fibrillation, ischemic heart disease and / or left ventricular dysfunction. The main consumption standards effects: anti arrhythmic effect, acting on ?1 and ?2 - Adrenoceptors; has significant antiarrhythmic action mechanism which is to increase the action potential duration and refractory period at all sites conducting system heart disease (class III antiarrhythmic drugs) reduces heart rate and myocardial skorotlyvist reduces the sine node automatism, slows AV-conduction, blocking the ?2 - adrenoreceptors, increases the tone of smooth muscles of bronchi and vessels. Parenterally Papanicolaou Stain severe disturbances of cardiac rhythm when treatment by oral preparatuu inappropriate, such as: Atrial fibrillation with high ventricular rate cuts; tachycardia associated with c-IOM WPW; documented symptomatic ventricular arrhythmias that lead to disability. Indications for use drugs: consumption standards tahiarytmiyi accompanied by clinical symptoms (including AV-/vuzlovi/paroksyzmalni tachycardia in WPW with-E or paroxysms of atrial fibrillation), prevention of paroxysms and flicker atrial flutter after restoration of sinus rhythm, ventricular cardiac rhythm consumption standards accompanied by clinical symptoms (tahiarytmiyi) and Prevention of proven effectiveness; arrhythmia caused by excessive circulation catecholamines or increased sensitivity to catecholamines.